EUVIMEDEUVIMED entdecken
Leserbrief

Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash

Giovanni Paolino iD, Dario Didona

Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8)

DOI: 10.1111/jdv.20688 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 07.04.2025. Verfasst von Giovanni Paolino und 1 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Autor:innen und Institutionen

  • Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Università Vita-Salute, San Raffaele, Milan, Italy.
  • Rare Skin Diseases Center, Istituto Dermopatico Dell'immacolata, IDI-IRCCS, Rome, Italy.

ORCID-Profile: Giovanni Paolino

Zitieren

APA

Paolino, G., & Didona, D. (2025). Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology, 39(8). https://doi.org/10.1111/jdv.20688

Vancouver

Paolino G, Didona D. Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology. 2025;39(8). doi:10.1111/jdv.20688

BibTeX
@article{Paolino2025,
  author = {Paolino, Giovanni and Didona, Dario},
  title = {Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {8},
  doi = {10.1111/jdv.20688}
}
Kostenlos starten →